Executive search firm Toft Group has placed Andrea Loewen-Rodriguez as Vice President, Regulatory Affairs and Quality Assurance at Retrophin in San Diego, CA. Ms. Loewen-Rodriguez is a global regulatory executive with 20+ years of pharmaceutical industry experience. She previously served at Vital Therapies as Vice President, Regulatory Affairs/ Quality where she was appointed to manage development and execution of U.S., EU, and RoW regulatory strategies. Prior to her role at Vital, Ms. Loewen-Rodriguez served at Shire Pharmaceuticals as Senior Director- Head, Global Regulatory Affairs- Regenerative Medicine. She earned her BA in Biology from Gustavus Adolphus College.
Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.